Lumos Non Currrent Assets Other vs Common Stock Analysis

LUMO Stock  USD 4.34  0.01  0.23%   
Lumos Pharma financial indicator trend analysis is infinitely more than just investigating Lumos Pharma recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lumos Pharma is a good investment. Please check the relationship between Lumos Pharma Non Currrent Assets Other and its Common Stock accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lumos Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.

Non Currrent Assets Other vs Common Stock

Non Currrent Assets Other vs Common Stock Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lumos Pharma Non Currrent Assets Other account and Common Stock. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Lumos Pharma's Non Currrent Assets Other and Common Stock is -0.14. Overlapping area represents the amount of variation of Non Currrent Assets Other that can explain the historical movement of Common Stock in the same time period over historical financial statements of Lumos Pharma, assuming nothing else is changed. The correlation between historical values of Lumos Pharma's Non Currrent Assets Other and Common Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Currrent Assets Other of Lumos Pharma are associated (or correlated) with its Common Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock has no effect on the direction of Non Currrent Assets Other i.e., Lumos Pharma's Non Currrent Assets Other and Common Stock go up and down completely randomly.

Correlation Coefficient

-0.14
Relationship DirectionNegative 
Relationship StrengthInsignificant

Non Currrent Assets Other

Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.

Common Stock

Most indicators from Lumos Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lumos Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lumos Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.At this time, Lumos Pharma's Selling General Administrative is very stable compared to the past year. As of the 12th of December 2024, Issuance Of Capital Stock is likely to grow to about 761.2 K, while Tax Provision is likely to drop (44.1 K).
 2021 2022 2023 2024 (projected)
Interest Expense484K874K1.0M671.3K
Depreciation And Amortization203K49K44K41.8K

Lumos Pharma fundamental ratios Correlations

-0.540.520.710.990.60.52-0.99-0.020.560.990.590.070.990.570.120.0-0.27-0.110.530.620.370.591.0-0.230.58
-0.54-0.65-0.42-0.560.24-0.110.590.35-0.2-0.550.26-0.69-0.56-0.320.45-0.550.320.25-0.39-0.67-0.120.25-0.570.39-0.06
0.52-0.650.780.480.020.19-0.51-0.550.450.490.00.320.490.29-0.20.02-0.330.140.60.690.41-0.020.54-0.170.48
0.71-0.420.780.640.490.38-0.66-0.140.810.660.480.080.650.31-0.01-0.19-0.240.030.860.460.660.480.71-0.060.5
0.99-0.560.480.640.580.48-0.99-0.050.480.990.560.040.990.570.130.06-0.4-0.120.450.660.210.570.99-0.190.57
0.60.240.020.490.580.34-0.570.130.590.591.0-0.490.590.120.47-0.52-0.17-0.110.370.150.260.990.570.080.66
0.52-0.110.190.380.480.34-0.460.38-0.030.470.35-0.420.510.390.59-0.10.090.460.1-0.030.380.340.52-0.130.15
-0.990.59-0.51-0.66-0.99-0.57-0.460.1-0.52-1.0-0.55-0.14-1.0-0.51-0.06-0.020.290.17-0.47-0.66-0.31-0.55-0.990.24-0.6
-0.020.35-0.55-0.14-0.050.130.380.1-0.05-0.080.15-0.39-0.060.290.30.160.320.06-0.06-0.70.120.22-0.030.13-0.58
0.56-0.20.450.810.480.59-0.03-0.52-0.050.520.590.170.50.13-0.11-0.18-0.09-0.290.890.30.60.60.55-0.130.42
0.99-0.550.490.660.990.590.47-1.0-0.080.520.580.111.00.510.08-0.01-0.29-0.160.460.650.310.570.99-0.220.61
0.590.260.00.480.561.00.35-0.550.150.590.58-0.480.580.110.47-0.54-0.11-0.110.360.120.30.990.560.070.66
0.07-0.690.320.080.04-0.49-0.42-0.14-0.390.170.11-0.480.09-0.01-0.820.360.18-0.530.250.370.22-0.50.1-0.37-0.14
0.99-0.560.490.650.990.590.51-1.0-0.060.51.00.580.090.510.110.01-0.28-0.140.460.630.310.570.99-0.230.6
0.57-0.320.290.310.570.120.39-0.510.290.130.510.11-0.010.510.130.14-0.10.120.140.360.170.130.58-0.160.05
0.120.45-0.2-0.010.130.470.59-0.060.3-0.110.080.47-0.820.110.13-0.22-0.010.62-0.17-0.19-0.030.480.1-0.20.21
0.0-0.550.02-0.190.06-0.52-0.1-0.020.16-0.18-0.01-0.540.360.010.14-0.22-0.23-0.05-0.02-0.01-0.34-0.440.02-0.31-0.57
-0.270.32-0.33-0.24-0.4-0.170.090.290.32-0.09-0.29-0.110.18-0.28-0.1-0.01-0.230.02-0.12-0.540.57-0.15-0.28-0.32-0.26
-0.110.250.140.03-0.12-0.110.460.170.06-0.29-0.16-0.11-0.53-0.140.120.62-0.050.02-0.17-0.140.04-0.11-0.11-0.010.01
0.53-0.390.60.860.450.370.1-0.47-0.060.890.460.360.250.460.14-0.17-0.02-0.12-0.170.320.640.380.52-0.170.27
0.62-0.670.690.460.660.15-0.03-0.66-0.70.30.650.120.370.630.36-0.19-0.01-0.54-0.140.32-0.030.080.63-0.210.65
0.37-0.120.410.660.210.260.38-0.310.120.60.310.30.220.310.17-0.03-0.340.570.040.64-0.030.260.37-0.30.19
0.590.25-0.020.480.570.990.34-0.550.220.60.570.99-0.50.570.130.48-0.44-0.15-0.110.380.080.260.560.070.59
1.0-0.570.540.710.990.570.52-0.99-0.030.550.990.560.10.990.580.10.02-0.28-0.110.520.630.370.56-0.240.56
-0.230.39-0.17-0.06-0.190.08-0.130.240.13-0.13-0.220.07-0.37-0.23-0.16-0.2-0.31-0.32-0.01-0.17-0.21-0.30.07-0.24-0.03
0.58-0.060.480.50.570.660.15-0.6-0.580.420.610.66-0.140.60.050.21-0.57-0.260.010.270.650.190.590.56-0.03
Click cells to compare fundamentals

Lumos Pharma Account Relationship Matchups

Lumos Pharma fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets96.8M129.0M100.3M72.3M40.6M38.6M
Short Long Term Debt Total1.2M319K557K233K585K555.8K
Other Current Liab10.2M5.6M3.8M6.0M5.6M5.8M
Total Current Liabilities11.8M6.5M5.1M6.7M7.0M11.8M
Total Stockholder Equity78.9M116.6M89.0M59.6M27.3M25.9M
Property Plant And Equipment Net2.4M584K635K283K603K572.9K
Net Debt(89.3M)(98.4M)(94.3M)(55.8M)(34.5M)(36.2M)
Retained Earnings(334.0M)(66.0M)(96.4M)(127.5M)(161.5M)(169.6M)
Accounts Payable475K244K612K275K890K845.5K
Cash90.5M98.7M94.8M56.0M35.1M33.3M
Non Current Assets Total2.4M584K635K283K603K572.9K
Non Currrent Assets Other735K(584K)(635K)(283K)(325.5K)(341.7K)
Cash And Short Term Investments90.5M98.7M94.8M67.4M36.1M34.3M
Net Receivables824K26.3M128K223K210K199.5K
Common Stock Total Equity372K373K12K83K74.7K71.0K
Common Stock Shares Outstanding144.7K6.8M8.3M8.4M8.1M4.1M
Liabilities And Stockholders Equity96.8M129.0M100.3M72.3M40.6M38.6M
Non Current Liabilities Total6.9M6.1M6M6.2M6.3M6.0M
Other Current Assets3.0M3.5M4.7M4.4M3.7M6.2M
Other Stockholder Equity412.5M311.5M185.3M187.0M188.7M223.2M
Total Liab17.9M12.5M11.3M12.7M13.3M21.4M
Property Plant And Equipment Gross457K584K635K283K603K572.9K
Total Current Assets94.4M128.4M99.7M72.0M40.0M38.0M
Accumulated Other Comprehensive Income(6.6M)(7.0M)(63.5M)(129.0M)0.0(9K)
Short Term Debt1.1M638K704K466K564K579.2K
Common Stock373K374K83K82K81K77.0K
Net Tangible Assets78.9M116.6M89.0M59.6M68.5M104.9M
Retained Earnings Total Equity(237.5M)(291.0M)(334.0M)(66.0M)(59.4M)(62.4M)
Capital Surpluse389.8M407.2M414.0M182.5M209.9M293.4M
Property Plant Equipment1.6M335K635K283K254.7K242.0K
When determining whether Lumos Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lumos Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lumos Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lumos Pharma Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lumos Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.
You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lumos Pharma. If investors know Lumos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lumos Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.28)
Revenue Per Share
0.27
Quarterly Revenue Growth
102.714
Return On Assets
(0.70)
Return On Equity
(1.73)
The market value of Lumos Pharma is measured differently than its book value, which is the value of Lumos that is recorded on the company's balance sheet. Investors also form their own opinion of Lumos Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lumos Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lumos Pharma's market value can be influenced by many factors that don't directly affect Lumos Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lumos Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lumos Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lumos Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.